TuHURA Biosciences Inc. (NASDAQ: HURA) announced the appointment of Amanda Garofalo as Senior Vice President of Clinical Operations. Garofalo will oversee day-to-day clinical operations and work with Craig Tendler, according to a company statement.

The appointment comes as the immuno-oncology company advances multiple clinical programs, including its IFx-2.0 Phase 3 trial, TBS-2025 Phase 1b/2 trial, and pre-clinical planning for antibody drug conjugates.

Garofalo brings over 20 years of clinical development experience to the role. She previously worked at Parabilis Medicines, where she supported activities leading to a $305 million Series F funding round. Before that, she served as Head of Oncology Delivery at EMD Serono, overseeing more than 200 oncology clinical trials across Phase I-IV development.

Her background also includes directing three new IND submissions at Arcus Biosciences and positions at Indivior, Medimmune, and GlaxoSmithKline Pharmaceuticals. Garofalo holds a Master of Science in Health Science with a focus in Clinical Research Administration from George Washington University and completed an Advanced Management Program at The Wharton School of Business.

"Her extensive experience across all stages of biotech drug development will greatly enhance our efforts," said James Bianco, President and Chief Executive Officer of TuHURA Biosciences.

TuHURA develops therapeutics designed to overcome resistance to cancer immunotherapy and is currently in Phase 3 development.